Pseudomyxoma peritonei

Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

Retrieved on: 
Monday, October 17, 2022
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Colon, Therapy, Neoplasm, EMA, Hyponatremia, NASDAQ, Antibody, Lymphocytopenia, SD, University, Abdominal distension, Primary sclerosing cholangitis, Association, Pseudomyxoma peritonei, CEO, Toxic leukoencephalopathy, University of California, San Francisco, Mesothelioma, UCSF, Database administrator, Population, Data, HIV disease progression rates, Cancer, Private Securities Litigation Reform Act, TRT, Department, Literature, Peptide, FDA, Isotope, RECIST, FAP, EANM, Kidney, Research, Security (finance), Cell, Trial of the century, Gallium, U.S. Securities and Exchange Commission, Radiation, Clovis Oncology, View, Sarcoma, Patient, Radiology, Gallbladder cancer, Drug discovery, Molecular Therapy, Toxicity, Safety, Biomedicine, Pharmaceutical industry, Medical imaging, Pharmacokinetics

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation at the 35th Annual European Association of Nuclear Medicine Congress (EANM) detailing updated Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study (NCT04939610) investigating the safety, pharmacokinetics, dosimetry, and preliminary anti-tumor activity of its targeted radiotherapy candidate, FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286).

Key Points: 
  • Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation at the 35th Annual European Association of Nuclear Medicine Congress (EANM) detailing updated Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study (NCT04939610) investigating the safety, pharmacokinetics, dosimetry, and preliminary anti-tumor activity of its targeted radiotherapy candidate, FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286).
  • The Phase 1 portion of the LuMIERE study is evaluating the safety of the investigational therapeutic agent 177Lu-FAP-2286 to identify the recommended Phase 2 dose and schedule.
  • The LuMIERE trial is the first prospective trial of a FAP peptide targeted radionuclide therapy and is currently in the dose escalation phase.
  • Updated results from the Phase 1 portion of the ongoing Phase 1/2 LuMIERE study found treatment-emergent adverse events (TEAEs) were mostly Grade 1 and 2 across cohorts.

Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting

Retrieved on: 
Tuesday, June 14, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Radiation, SNMMI, Clovis Oncology, Associate, Abdominal distension, Therapy, Isotope, PT, FAP, View, Cancer, RECIST, U.S. Securities and Exchange Commission, Mesothelioma, Sarcoma, Marnix, CEO, Society, Back pain, Pseudomyxoma peritonei, Trial of the century, Antibody, Clinical research coordinator, Colon, Population, Molecular imaging, University, Patient, Cell, EMA, Abstract, Security (finance), Gallium, Hyponatremia, CEA, Private Securities Litigation Reform Act, Research, Neoplasm, UCSF, University of California, San Francisco, Toxic leukoencephalopathy, FDA, Division, TRT, NASDAQ, SAE, Drug discovery, Peptide, Safety, Database administrator, Pharmaceutical industry, Vaccine, Medical imaging, Radiology, Pharmacokinetics

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation detailing initial Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study (NCT04939610) investigating the safety, pharmacokinetics, dosimetry, and preliminary antitumor activity of its targeted radiotherapy candidate, FAP-2286 labelled with lutetium-177 (177Lu-FAP-2286).

Key Points: 
  • Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation detailing initial Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study (NCT04939610) investigating the safety, pharmacokinetics, dosimetry, and preliminary antitumor activity of its targeted radiotherapy candidate, FAP-2286 labelled with lutetium-177 (177Lu-FAP-2286).
  • FAP-2286 is the first peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting FAP to enter clinical development and is the lead candidate in Clovis Oncologys targeted radionuclide therapy (TRT) development program.
  • The Phase 1 portion of the LuMIERE study is evaluating the safety of the investigational therapeutic agent 177Lu-FAP-2286 to identify the recommended Phase 2 dose and schedule.
  • FAP-2286 is a clinical candidate under investigation as a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP).

Grifols acquires Tiancheng Pharmaceutical Holdings, the largest shareholder of Biotest, to increase patients' access to plasma therapies

Retrieved on: 
Friday, September 17, 2021
Quality of life, Hematology, BofA Securities, VWAP, MCE, Plasma, Health, Economics, Pharmacy, Transfusion medicine, Patient, Fibrinogen, Immunoglobulin M, Frankfurt Stock Exchange, PMP, Clinical trial, GRF, Safety, Hospital, Industry, NASDAQ, Legislation, Pseudomyxoma peritonei, Solution, EUR, Proskauer Rose, S.A, SCAP, Acquisition, Community-acquired pneumonia, Sale, Fine chemical, Security (finance), Pharmaceutical industry, Film, Management

This transaction reflects how Biotest and Grifols live out its missions and jointly advance towards increasing global plasma-derived therapies availability while meeting patients' needs around the world.

Key Points: 
  • This transaction reflects how Biotest and Grifols live out its missions and jointly advance towards increasing global plasma-derived therapies availability while meeting patients' needs around the world.
  • This acquisition will significantly reinforce Grifols' industry capabilities by enhancing its plasma-derived medicines access, pipeline and sales presence.
  • It will also improve Grifols' plasma economics and revenue per liter bringing innovative plasma proteins to drive revenue growth and margin expansion.
  • The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.